Intellia Therapeutics (NASDAQ: NTLA) Gains Momentum with Analyst Target Hike and FDA Priority Review
| Show full article |
|
This functionality is available for registred users only
|
-
Full nameIntellia Therapeutics Inc.
-
Registration countryUSA
-
IndustryPharmaceutical Preparation and Biotechnology
-
М/S&P/F
*** /*** /***









